Clin Psychopharmacol Neurosci.  2017 Aug;15(3):199-209. 10.9758/cpn.2017.15.3.199.

Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines

  • 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 2Department of Psychiatry, Konkuk University School of Medicine, Chungju, Korea.
  • 3Department of Psychiatry, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
  • 4Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • 5Department of Psychiatry, Inje University Seoul Paik Hospital, Inje University School of Medicine, Seoul, Korea.
  • 6Stress Research Institute, Inje University, Seoul, Korea.
  • 7Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • 8Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • 9Paik Institute for Clinical Research, Inje University, Busan, Korea.
  • 10Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
  • 11Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
  • 12Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea.


In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.


Depressive disorder; Expert consensus; Guideline; KMAP-DD 2017; Therapy
Full Text Links
  • CPN
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: